Argenx expands oral therapeutic pipeline through Unnatural Products acquisition
Argenx has agreed to acquire Unnatural Products for $550 million upfront, gaining a macrocyclic peptide platform to develop oral treatments for immune-mediated diseases.
Argenx has acquired Unnatural Products, integrating its macrocyclic peptide platform to develop oral therapies for immune-mediated diseases. The Netherlands-based biotechnology company announced the deal on November 9, 2026, paying $550 million upfront with potential milestone payments adding up to $595 million more.
The acquisition adds a macrocyclic peptide discovery platform to Argenx's immunology pipeline. This technology uses machine learning and screening techniques to engineer peptides that bind to difficult-to-target proteins. Argenx previously held a minority stake in Unnatural Products before pursuing the full acquisition.
Financial Terms
The transaction includes a $550 million upfront payment with up to $595 million in milestone payments, totaling $1.15 billion.
| Payment Component | Amount (USD) | Condition |
|---|---|---|
| Upfront Cash | $550 million | Paid upon deal closure |
| Milestone Payments | Up to $595 million | Tied to development and regulatory achievements |
| Potential Total | Up to $1.15 billion | If all milestones are met |
Unnatural Products could receive the additional $595 million upon achieving specific development and regulatory milestones. The boards of both companies have approved the transaction, which is expected to close before the end of 2026, subject to customary closing conditions.
Strategic Rationale
The acquisition strengthens Argenx's oral therapeutic pipeline and aligns with industry goals for long-acting treatments in immunology. Argenx plans to develop oral, durable medicines for serious immune-mediated diseases using the platform. It is intended to broaden the company's ability to pursue novel biology.
Analyst Thomas Smith of Leerink Partners noted the acquisition offers potential for longer-term strategic value. He said it aligns with industry goals for oral, long-acting therapeutics. The deal follows Argenx's $2.2 billion acquisition of Forte Biosciences earlier in the year.
Argenx's flagship product Vyvgart generated $4.5 billion in net product sales from January through September 2026. Following the acquisition announcement, Argenx's shares rose nearly 3% to around $953 per share. The BEL 20 index also moved into record territory at midday, with Argenx identified as its strongest positive influence.
Regulatory and Clinical Context
Macrocyclic peptides have received FDA approval for various indications, supporting the platform's therapeutic potential. These molecules are larger and more complex than typical small molecules but can be swallowed.
| Therapy | FDA Approval Year | Indication |
|---|---|---|
| Imcivree | 2020 | Genetic obesity |
| Lupkynis | 2021 | Lupus nephritis |
| Zilbrysq | 2023 | Generalized myasthenia gravis |
This regulatory history provides a foundation for developing new oral therapies. Unnatural Products is expected to continue operating from its Santa Cruz, California site after the deal closes. That location will become Argenx's peptide discovery hub.
Argenx will contribute clinical development and commercialization capabilities to the partnership. Unnatural Products will continue its discovery work within an agreed strategic framework. The financial and pipeline impact remains linked to the deal's closing and the achievement of the specified milestones. The deal is expected to close by the end of 2026, pending customary conditions.
